Activation of adaptive immune processes for the treatment of cancers and infectious diseases
AssigneeSusavion Biosciences, Inc.
InventorsLaura L. Eggink, J. Kenneth Hoober
Life of this patent
Estimating the term…
Abstract
Polypeptides, such as a multi-valent polypeptide designated svD2, useful in pharmaceutical compositions for stimulation of the adaptive arm of the immune system. svD2 demonstrated in vivo activity in a syngeneic mouse model. svD2 is biologically active at nanomolar concentrations. These properties are believed to result as a consequence of the ability of svD2 to cross-link cell-surface receptors.
Claims28
A method for treating cancer, the method comprising administering to a subject having cancer a polypeptide comprising an amino acid sequence of VSNQH (SEQ ID NO:1) in an amount sufficient to treat cancer.
A method for increasing the survival period of a subject diagnosed as having a tumor, the method comprising administering to the subject a polypeptide comprising an amino acid sequence of VSNQH (SEQ ID NO:1) in an amount sufficient to increase the subject's survival period.
A method for increasing the survival rate of a subject diagnosed as having a tumor, the method comprising administering to the subject a polypeptide comprising an amino acid sequence of VSNQH (SEQ ID NO:1) in an amount sufficient to increase the subject's survival rate.
The method of any one of the preceding claims, wherein the polypeptide comprises the amino acid sequence of VSNQH (SEQ ID NO:1) and a spacer sequence GGGS (SEQ ID NO:3).
The method of any one of the preceding claims, wherein the polypeptide is branched and the cancer is ovarian or melanoma.
The method of any one of the preceding claims, wherein the polypeptide is administered systemically to bind to receptors on immune cells.
The method of any one of the preceding claims, wherein administration of the polypeptide stimulates production of progenitor/precursor cells in the peritoneal cavity.
The method of any one of the preceding claims, wherein administration of the polypeptide induces maturation and activation of immune cells in the peritoneal cavity.
The method of any one of the preceding claims, wherein administration of the polypeptide causes an increase in mature cells, including T and B lymphocytes, cytotoxic T cells and natural killer cells.
The method of any one of the preceding claims, wherein administration of the polypeptide stimulates migration of mature immune cells from the peritoneal cavity into the blood.
The method of any one of the preceding claims, wherein administration of the polypeptide stimulates release of cytokines beneficial for destruction of cancer cells or an infectious agent.
The method of any one of the preceding claims, wherein beneficial cytokines released in in cultures of peripheral blood mononuclear cells include Eotaxin, IL-17, IL-21, TNFα, Lymphotoxin-α (TNFβ), and MCP-2.
The method of any one of the preceding claims, wherein the polypeptide is administered as a complement to another therapy.
The method of any one of the preceding claims, wherein the polypeptide is administered in an aqueous pharmaceutical composition having a polypeptide concentration from about 0.1 to about 10 mM and a pharmaceutically acceptable carrier.
The method of any one of the preceding claims, wherein the polypeptide, compared to IFNγ, induces a greater release of the cytokine IL-21 in a cytokine release assay.
The method of any one of the preceding claims, wherein the polypeptide does not stimulate phagocytosis, based on comparison of internalization of bacterial cells by PBMCs stimulated with IFNγ.
The method of any one of the preceding claims, wherein the polypeptide stimulates the immune system, based on increased density of one or more cellular markers on peritoneal cells.
Dependencies are inferred from the claim text.